Neuroleptic malignant syndrome (NMS) is associated with essentially all of the currently available
antipsychotic agents. The signs and symptoms associated with the syndrome are
hyperpyrexia, defined by body temperature greater than 38 degrees C; extreme
muscle rigidity, with or without elevated
creatine phosphokinase or
hyperreflexia; and other symptoms such as
altered level of consciousness and/or autonomic dysfunction as manifested by labile blood pressure,
tachycardia,
tachypnea, urinary or
fecal incontinence, pallor, or diaphoresis. This potentially fatal syndrome complicates the treatment of patients with recurrent psychotic symptoms because of the possibility for recurrence of the NMS. A case of recurrent NMS is presented in which the patient was rechallenged with an
antipsychotic agent. In addition, 41 reported cases of
antipsychotic rechallenge after NMS are reviewed. The results of the review suggest that
neuroleptic rechallenge following NMS is associated with an acceptable risk of recurrence in most patients. However, close monitoring for NMS and careful selection of patients for
antipsychotic rechallenge is mandatory. A minimal time period of five days before rechallenge may also reduce the risk of recurrent NMS. Recurrence was not associated with patient age or gender, nor the
antipsychotic agent used.